Treatment of Non-Small-Cell Lung Cancer with Erlotinib following Gefitinib-Induced Hepatotoxicity: Review of 8 Clinical Cases

Lung Cancer International
Yukihiro YanoSoichiro Yokota

Abstract

Objective. Gefitinib often induces liver damage. A few reports have described that the subsequent administration of erlotinib was associated with less hepatotoxicity, but the safety and efficacy of this treatment are still not fully investigated. Therefore, we evaluated retrospectively the patients with erlotinib following gefitinib-induced hepatotoxicity. Methods and Patients. We retrospectively reviewed the medical records between December 2007 and March 2010. The patients were evaluated including the following information: age, gender, histology of lung cancer, performance status, smoking status, epidermal growth factor receptor (EGFR) mutation status, liver metastasis, viral hepatitis, alcoholic liver injury, clinical response, and hepatotoxicity due to EGFR tyrosine kinase inhibitors. Results. We identified 8 patients with erlotinib following gefitinib-induced hepatotoxicity. All achieved disease control by gefitinib. Hepatotoxicity was grades 2 and 3 in 3 and 5 patients, respectively. The median duration of treatment with gefitinib was 112.5 days and the median time to gefitinib-induced hepatotoxicity was 51.5 days. The median duration of treatment with erlotinib was 171.5 days. Grade 1 and 2 erlotinib-induced hepatotoxic...Continue Reading

References

Aug 27, 2004·Proceedings of the National Academy of Sciences of the United States of America·William PaoHarold Varmus
Nov 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cheryl HoNevin Murray
Jul 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nobuhiko SekiKenji Eguchi
Dec 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paolo CarliniGianluigi Ferretti
Jun 19, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jing LiSharyn D Baker
Jun 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Byoung Chul ChoJoo Hang Kim
Jul 23, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D H LeeJ-S Lee
Sep 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Riichiroh MaruyamaMasahiro Fukuoka
Dec 6, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Kaoru KubotaNagahiro Saijo
Dec 27, 2008·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Sung Hoon SimYung-Jue Bang
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Aug 21, 2009·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Tatsuya KatayamaTetsuya Mitsudomi
Nov 10, 2009·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Hiroshige YoshiokaUNKNOWN Okayama Lung Cancer Study Group
Apr 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Masayuki TakedaKazuhiko Nakagawa
Jun 25, 2010·The New England Journal of Medicine·Makoto MaemondoUNKNOWN North-East Japan Study Group
Aug 26, 2010·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Martin ReckDavid Heigener
Sep 8, 2010·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Geoffrey Y KuGilberto de Lima Lopes
Apr 20, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Takashi KijimaIchiro Kawase

❮ Previous
Next ❯

Citations

May 18, 2016·Expert Opinion on Drug Metabolism & Toxicology·Kirsty Wai-Chung Lee, Stephen Lam Chan
May 24, 2016·Expert Opinion on Drug Safety·Emily Han-Chung HsiueJames Chih-Hsin Yang
Nov 9, 2020·Critical Reviews in Oncology/hematology·Camille HouronCosmin Sebastian Voican

❮ Previous
Next ❯

Software Mentioned

IPASS

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.